Zacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.68 Earnings Per Share

Equities analysts expect that Urogen Pharma Ltd (NASDAQ:URGN) will post earnings per share (EPS) of ($0.68) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Urogen Pharma’s earnings, with the lowest EPS estimate coming in at ($0.69) and the highest estimate coming in at ($0.67). The company is scheduled to issue its next earnings results on Friday, May 4th.

On average, analysts expect that Urogen Pharma will report full year earnings of ($1.88) per share for the current year, with EPS estimates ranging from ($2.05) to ($1.59). For the next year, analysts expect that the firm will report earnings of ($2.59) per share, with EPS estimates ranging from ($2.95) to ($2.11). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Urogen Pharma.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.10).

Several analysts have issued reports on URGN shares. Jefferies Group increased their target price on Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, October 9th. Zacks Investment Research raised Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, October 18th. Oppenheimer set a $51.00 target price on Urogen Pharma and gave the company an “outperform” rating in a research report on Tuesday, November 14th. UBS Group cut Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 15th. Finally, Raymond James Financial cut Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 15th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $39.00.

In other news, major shareholder Proquest Investments Iv, L.P. sold 209,298 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $40.60, for a total value of $8,497,498.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

A number of institutional investors and hedge funds have recently modified their holdings of URGN. FMR LLC purchased a new position in shares of Urogen Pharma during the 2nd quarter valued at about $13,892,000. Menora Mivtachim Holdings LTD. increased its stake in shares of Urogen Pharma by 341.4% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 569,589 shares of the company’s stock valued at $17,953,000 after purchasing an additional 440,534 shares in the last quarter. DSAM Partners London Ltd purchased a new position in shares of Urogen Pharma in the 3rd quarter valued at about $2,348,000. Bainco International Investors purchased a new position in shares of Urogen Pharma in the 3rd quarter valued at about $2,284,000. Finally, Lyon Street Capital LLC purchased a new position in shares of Urogen Pharma in the 3rd quarter valued at about $1,316,000. 32.16% of the stock is owned by institutional investors.

Shares of Urogen Pharma (NASDAQ URGN) traded up $1.95 during midday trading on Tuesday, reaching $47.17. The company’s stock had a trading volume of 66,183 shares, compared to its average volume of 148,750. Urogen Pharma has a 1-year low of $13.01 and a 1-year high of $56.56.

ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/06/zacks-brokerages-anticipate-urogen-pharma-ltd-urgn-to-announce-0-68-earnings-per-share.html.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply